Related Experiment Videos
Developmental outcome of premature infants treated with theophylline
Insights
Theophylline treatment for apnea in premature infants did not negatively impact long-term neurodevelopmental outcomes. This study found no adverse effects on somatic growth or severe neurologic sequelae in theophylline-exposed infants.
Area of Science:
- Neonatal Medicine
- Developmental Pediatrics
- Pharmacology
Background:
- Methylated xanthines, like theophylline, have known metabolic effects.
- Apnea is a common concern in premature infants requiring intervention.
Purpose of the Study:
- To investigate the developmental outcomes of premature infants treated with theophylline for neonatal apnea.
- To assess the long-term effects of neonatal theophylline exposure on development.
Main Methods:
- Comparative study of premature infants treated with theophylline versus those not treated.
- Assessment of Apgar scores, gestational age, developmental indices, neurologic sequelae, retrolental fibroplasia, and somatic growth.
- Follow-up evaluation at 9–27 months of age.
Main Results:
- Theophylline-treated infants had lower Apgar scores and gestational ages.
- No significant differences were observed in developmental indices between groups.
- Incidences of severe neurologic sequelae, retrolental fibroplasia, and somatic growth were similar in both groups.
Conclusions:
- Neonatal theophylline treatment for apnea does not appear to adversely affect the neurodevelopmental outcomes of premature infants.
- Theophylline is a potentially safe option for managing apnea in premature infants, with no observed long-term developmental detriments.
Abstract:
The methylated xanthines are known to have multiple metabolic effects. This study was performed to examine the development of premature infants treated with theophylline in the neonatal period for apnea. The theophylline-treated infants had lower Apgar scores and gestational ages when compared to those who did not receive theophylline. There were no significant differences in the developmental indices, and both groups had similar incidences of severe neurologic sequelae and retrolental fibroplasia. Similarly, there were no differences in the somatic growth. The data suggest that theophylline does not adversely affect development of premature infants when examined at 9--27 months of age.